Zacks Investment Research upgraded shares of Zealand Pharma A/S (NASDAQ:ZLDPF) from a sell rating to a hold rating in a research report sent to investors on Tuesday, July 25th.
According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “
Zealand Pharma A/S (NASDAQ ZLDPF) remained flat at $18.95 during trading on Tuesday. Zealand Pharma A/S has a 1-year low of $14.95 and a 1-year high of $19.51. The firm has a 50 day moving average of $18.19 and a 200-day moving average of $17.27. The stock’s market capitalization is $484.72 million.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.